INVESTOR MATERIALS

Humanigen Fact Sheets

Corporate
Cytokine Storm
Lenzilumab

Humanigen Corporate Presentation

October 2020

Lenzilumab COVID-19 Case-Control Study Published in Mayo Clinic Proceedings Journal

  • Mayo Clinic Proceedings Lenzilumab COVID-19 Case-Control Study
  • GM-CSF and Cytokine Storm in Coronavirus
  • A new role for an old cytokine: GM-CSF amplifies GVHD
  • Role of GM-CSF in acute GVHD
  • Graft-versus-host disease, but not graft-versus-leukemia immunity, is mediated by GM-CSF–licensed myeloid cells
  • Lenzilumab Study Published in ‘blood’
  • Humanigen GM-CSF Review
  • Lenzilumab at ASH 2018 - Abstract
  • Targeting EphA3 Inhibits Cancer Growth by Disrupting the Tumor Stromal Microenvironment
  • EphA3 Publication in 'Cancers'
  • Hypoxia-Controlled EphA3 Marks a Human Endometrium-Derived Multipotent Mesenchymal Stromal Cell that Supports Vascular Growth
  • Eosinophil surface receptor EMR1: a novel therapeutic target for eosinophilic disorders

CAR-T–cell neurotoxicity: hope is on the horizon

Editorial in Blood Journal

by Omar Ahmed

SEC FILINGS

STOCK DATA

High-resolution copies of Humanigen's logo are available to download for media usage here (.zip, 212 KB)
Humanigen Form 8937 available here.
CONTACTS
INVESTOR RELATIONS

Richard Brown
T: 857-226-3917

Rbrown@humanigen.com

AUDITOR

Horne LLP
1020 Highland Colony Parkway
Suite 400
Ridgeland, MS 39157

TRANSFER AGENT

Computershare Trust Company, N.A.
250 Royall Street
Canton, MA 02021
T: 800-662-7232
www.computershare.com

LEGAL COUNSEL

Polsinelli PC
900 West 48th Place
Suite 900
Kansas City, MO 64112

  • Twitter

©2020 Humanigen, Inc.  All rights reserved